Alcon is the global leader in eye care with over 75 years dedicated to helping people see brilliantly. Alcon offers a wide spectrum of eye care products in surgical, pharmaceutical and vision care.

We offer a complete line of ophthalmic surgical products, enabling surgeons to achieve optimal results for their patients. Our surgical portfolio includes technologies and devices for cataract, vitreoretinal, refractive surgery, as well as advanced technology intraocular lenses to treat cataracts and refractive errors, like presbyopia and astigmatism. Other implantables include Hydrus^® Microstent, a minimally invasive glaucoma surgery (MIGS) device. We also provide advanced viscoelastics, surgical solutions, visualisation, Custom Paks®, and other disposable products for cataract and vitreoretinal surgery.

Alcon has a strong commitment to its partnership with eye care professionals and humanitarian organisations locally and internationally.   Alcon is also proud to have recently launched its Reflect Reconciliation Action Plan with a vision to improve the quality of life of Aboriginal and Torres Strait Islander peoples across Australia by significantly improving eye health equity and creating employment, education, and business opportunities for First Nations peoples.

Apellis is an international biopharmaceutical company, headquartered in the United States and established in Australia in 2020. Our company is committed to leading the development of therapies that target the complement cascade of the immune system, leveraging courageous science and compassion to deliver life-changing medicines for patients.

Aspen Australia, is an affiliate of the International Aspen Group, commenced operations in Australia and New Zealand in May 2001. It is a large non-generic supplier of medicines with many product lines manufactured, distributed, and marketed in Australia. Aspen manages pharmaceutical products in most therapeutic categories including Prescription Pharmaceutical brands, Speciality pharmaceutical products, and OTC healthcare products.

Avant has supported doctors for over 130 years. We are Australia’s largest medical indemnity insurer, protecting over half of Australia’s doctors and are committed to a sustainable health system that provides quality care to the community.

Avant offers a broad range of products and services tailored for doctors to protect and support them throughout their careers and lives. These include health insurance, life insurance advice, practice solutions, lending solutions and legal advice.

As a member-owned organisation, we are run to benefit our doctor members and the communities they serve. Any profits are reinvested to benefit members and healthcare in Australia.

BOC Instruments is a well established supplier and service provider of the most reputable ophthalmic equipment

Our product range includes an extensive range of equipment including Frey Slit Lamps, Ultra-Wide field Retinal Camera, Optovue OCTs, Hand-held AutoRefractors, Chair & stands, innovative Dry Eye products, Acuity Charts and much more.

Our VF2000 NEO Virtual Reality portable Field Tester with eye tracking is an innovative device provides unsurpassed accuracy and efficiency at exceptional value which also includes abundant additional vision testing features.

We shall also be demonstrating the Frey range of products encompassing the CP-400 multi-functional digital acuity chart, AP600 Visual Field Analyser and the SLI200-4K Slit Lamp imaging system with unprecedented 4K resolution and clarity

Please visit our stand during the RANZCO NSW congress 2026.

Tailor made compounded medications by our highly trained and experienced pharmacists. We’re able to reproduce medications that are out of stock as well as working alongside doctors to formulate medications to suit individual patient needs. We work with dosage forms, ingredient combinations and strength variations. Our facility allows us to efficiently compound both sterile and non-sterile preparations to suit both doctor and patient’s needs, which meet the strict Australian standards. We use state-of-the art compounding equipment and use USP/BP grade ingredients. We can deliver medications anywhere in Australia with a quick turn around time of 24-48 hours.

EyeVantage is an Australian healthcare company that specialises in the management and supply of ophthalmic medications for eye clinics and day surgeries. By combining pharmacy services with integrated digital technology, EyeVantage helps ophthalmology practices streamline the prescribing, approval, dispensing, and delivery of medications used in intravitreal injections (IVIs) and post-operative eye care.

The EyeVantage model focuses on integrating pharmacy workflows directly into clinical systems, allowing medications to be ordered and prepared as part of the patient care process. This approach reduces administrative burden for clinic staff, simplifies prescription management, and ensures medications are ready for patients at the time they are needed.

EyeVantage supports practices through several key services, including IVI medication ordering for scheduled injections, emergency/spare stock management for unscheduled patients, and preparation of post-operative medication packs that allow patients to leave the clinic with all required medications immediately after surgery.

The company also develops tools that automate prescription workflows, including electronic prescription generation and integrated PBS authority approvals. These systems allow clinicians to obtain approvals and generate prescriptions within seconds, improving clinic efficiency.

By combining pharmacy expertise with innovative technology integration, EyeVantage aims to modernise medication management in ophthalmology and improve both clinic efficiency and patient experience.

Glaukos is an ophthalmic device and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

Innovation is at the core of everything we do. Our mission is to transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to push the limits of science and technology to disrupt and improve the legacy treatment paradigms in glaucoma, corneal disorders and retinal diseases.

With deep expertise in developing intelligent imaging and data management solutions, Heidelberg Engineering builds on its history of designing and manufacturing state-of-the-art ophthalmic diagnostic instruments.

Including SPECTRALIS, a multi-modal imaging platform for the posterior segment, offering unparalleled retinal image quality and reproducibility to support the diagnosis and treatment of glaucoma, age-related macular degeneration, diabetic retinopathy and other retinal diseases; ANTERION, an all-in-one anterior segment diagnostic and imaging platform, providing biometry and IOL power prediction, corneal topography, tomography, and anterior chamber metrics based solely on high-quality swept-source OCT.; HEYEX 2, an image management and device integration platform that supports diagnostic workflows.

IQ Medical is a leading Australian owned specialist ophthalmic company founded in 2002. We build strong collaborative partnerships with our clients nationwide through expert product knowledge and personalised service. We are driven to offer ophthalmic innovations that help transform patients’ lives. We choose global innovators who advance ophthalmic technology and partner with them to deliver products that help transform vision. Our focus is on shaping the future of eye health by embracing bold ideas and groundbreaking creativity.  For more information visit iqmedical.com.au.

iSTAR Medical is committed to delivering breakthrough eye care solutions. MINIject^® is iSTAR Medical’s innovative MIGS device for the treatment of open-angle glaucoma – the leading cause of irreversible blindness. MINIject^® combines the distinctive porous structure of its proprietary STAR material with the IOP-lowering power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. MINIject^® is approved in Europe, the UK and Australia.

Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. As a global leader in eye-health, we have a bold ambition: Vision Made Possible – and are paving the way for a new future of eye health to support the full spectrum of paediatric, developed and mature eyes. Through cutting-edge innovation, scientific expertise, and advanced technologies, we are revolutionising the way people see and experience the world. At every step of the eye health journey – from investigational gene therapies for retinal diseases to contact lenses and refractive and cataract surgical solutions – we stand as a trusted partner with the goal of making vision possible for customers and patients.

OptiMed is a trusted provider, delivering premium ophthalmic products and solutions to eyecare professionals across Australia and New Zealand. Since our founding in 1988, we’ve built a reputation for reliability, innovation, and exceptional service – supporting our customers to deliver outstanding patient care.

At Optos, we deliver comprehensive retinal imaging devices and evaluation tools to eyecare professionals globally.  Optos produce ultra-widefield optomap® images of up to 82% or 200◦ of the retina, something no other device can do in a single capture.

An optomap® image provides a bigger picture and more clinical information, facilitating the early detection, management and effective treatment of disorders and diseases evidenced in the retina. With the support of over 2000 peer reviewed clinical studies, optomap® is the only clinically validated, ultra-widefield retinal imaging technology in the industry.

We continue to strengthen our clinical evidence and expand disease indications to demonstrate the importance of imaging the entire retina and it’s what drives our singular focus on delivering the world’s ONLY ultra-widefield retinal imaging technology.

Our passion has made optomap® the gold standard in eye care and we are committed to utilising the latest technology, manufacturing new products and software that support optomap® to assist eyecare professionals around the world save sight and lives.

Rayner is leading the way in ophthalmic innovation with IOLs and ophthalmic solutions designed to provide surgeons and patients with the best visual outcomes. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention. Rayner has a broad portfolio of products across the patient pathway, including monofocal and premium Intraocular Lenses (IOLs) including Galaxy – the world’s first spiral IOL, Ophthalmic Viscosurgical Devices (OVDs), the Sophi Phaco platform and RayPRO, our patient outcomes digital platform.
Rayner is a British company and the only manufacturer of intraocular lenses in the UK.

A healthier future – that’s what drives us. Throughout our 128-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.

Our commitment to our people, partners, stakeholders and, most importantly, patients remains as strong as it was on the first day of our journey.

At Roche, we are doing now what patients need next. We have a global ambition to deliver 20 transformative medicines by 2030, addressing diseases with the highest societal burden. Our focus is on end-to-end investment in 11 diseases across 5 therapy areas which account for the bulk of global disease burden: oncology & haematology, neurology, ophthalmology, immunology and cardiovascular-metabolism.

With a heritage in respect for a healthy planet, Roche’s sustainability approach supports the UN Sustainable Development Goals. We are committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz annually, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.

The Carl Zeiss Group is a leading group of companies operating worldwide in the optical and opto-electronic industries. Headquartered in Oberkochen, Germany, Carl Zeiss is represented in more than 50 countries ZEISS has pioneered many ground-breaking ophthalmological technologies and leads the way in various fields in the clinic and theatre environment.